For years, peripheral vascular intervention has attracted companies
and analysts like JuneBugs to Bug Zappers, and with similar end results
in many cases. While the promise of effectively treating narrowed or
blocked arteries in the leg is indeed a potentially multibillion dollar
promise, experienced investors have learned just how hard it is to
translate that promise into real income and cash flow.
Cardiovascular Systems (CSII)
has gone on this familiar ride. While the company seems to have
developed a legitimately better mousetrap, one for which there is strong
supporting clinical data, the company has struggled to drive consistent
utilization growth and profit leverage. Although I'm somewhat skeptical
of the company's ability to generate value for investors on stand-alone
basis, the value of this company to a strategic buyer could be
impressive.
Please continue here:
Cardiovascular Systems Could Have A Much Higher Value To A Strategic Buyer
No comments:
Post a Comment